Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NITIN YOGENDRA BHATT

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1801809256
CMS profile
36243
Location
COLUMBUS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$712.93

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Boehringer Ingelheim Pharmaceuticals, Inc. $652.14 7
Genentech USA, Inc. $60.79 2

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NITIN YOGENDRA BHATT

NPI 1801809256 · CMS profile ID 36243

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

COLUMBUS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801809256?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NITIN YOGENDRA BHATT, NPI 1801809256, CMS profile ID 36243. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801809256?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NITIN YOGENDRA BHATT, NPI 1801809256, CMS profile ID 36243. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801809256?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NITIN YOGENDRA BHATT, NPI 1801809256, CMS profile ID 36243, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1801809256?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $712.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $73.9811/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749863475 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $76.1310/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749863509 CMS
Genentech USA, Inc. $22.7910/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681331339 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $67.6910/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700069827 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $130.5010/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700069833 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.1905/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700039993 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $193.8905/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700069829 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $83.7605/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700069831 CMS
Genentech USA, Inc. $38.0002/18/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681237287 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $712.93 9
PY2021 $2.50 1
PY2022 $515.55 2
PY2023 $6,498.94 11
PY2024 $234.40 3
PY2025 $9,435.99 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $211,160.76 114
PY2024 Principal investigator $233,520.31 40
PY2023 Principal investigator $230,056.11 21
PY2022 Principal investigator $105,854.84 6
PY2021 Principal investigator $35,604.31 45
PY2020 Principal investigator $38,628.32 29
PY2019 Principal investigator $4,137.43 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

114 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 United Therapeutics Corporation $2,346.12 12/24/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389355
Principal investigator 1 United Therapeutics Corporation $2,420.60 12/24/2025 Non-covered Recipient Entity
The Ohio State University
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389371
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 12/17/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786509
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 12/17/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786511
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 12/17/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786513
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $280.00 12/03/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794281
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 12/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786503
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 12/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786505
Principal investigator 1 United Therapeutics Corporation $750.96 11/26/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389347
Principal investigator 1 United Therapeutics Corporation $2,099.16 11/26/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389353
Principal investigator 1 United Therapeutics Corporation $2,165.80 11/26/2025 Non-covered Recipient Entity
The Ohio State University
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389369
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,275.60 11/25/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220794265
Principal investigator 1 United Therapeutics Corporation $1,690.00 11/14/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242389393
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,950.08 11/13/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220794263
Principal investigator 1 United Therapeutics Corporation $6,914.88 11/12/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389361
Principal investigator 1 United Therapeutics Corporation $7,134.40 11/12/2025 Non-covered Recipient Entity
The Ohio State University
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389377
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 11/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786499
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 11/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786501
Principal investigator 1 United Therapeutics Corporation $877.50 10/29/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242389389
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,622.40 10/28/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794279
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 10/27/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786507
Principal investigator 1 United Therapeutics Corporation $5,920.34 10/24/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242389399
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 10/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786495
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 10/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786497
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 09/24/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786487
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 09/24/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786489
Principal investigator 1 Boehringer Ingelheim International GmbH $3.36 09/24/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786491
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 09/24/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786493
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,330.35 09/24/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794241
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,013.00 09/18/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794277
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,035.81 09/04/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794239
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 09/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786483
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 09/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786485
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,274.00 08/15/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794275
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786479
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 08/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786481
Principal investigator 1 United Therapeutics Corporation $7,560.00 07/23/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389363
Principal investigator 1 United Therapeutics Corporation $11,175.00 07/23/2025 Non-covered Recipient Entity
The Ohio State University
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389379
Principal investigator 1 United Therapeutics Corporation $526.50 07/18/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242389385
Principal investigator 1 United Therapeutics Corporation $600.00 07/18/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242389387
Principal investigator 1 United Therapeutics Corporation $975.00 07/18/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242389391
Principal investigator 1 United Therapeutics Corporation $3,000.00 07/18/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242389395
Principal investigator 1 United Therapeutics Corporation $5,160.00 07/18/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242389397
Principal investigator 1 United Therapeutics Corporation $10,172.83 07/18/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242389401
Principal investigator 1 United Therapeutics Corporation $10,400.00 07/18/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242389403
Principal investigator 1 United Therapeutics Corporation $4,445.28 07/08/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389359
Principal investigator 1 United Therapeutics Corporation $4,586.40 07/08/2025 Non-covered Recipient Entity
The Ohio State University
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389375
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 07/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786475
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 07/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786477
Principal investigator 1 United Therapeutics Corporation $750.96 06/25/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389345
Principal investigator 1 United Therapeutics Corporation $3,704.40 06/11/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389357
Principal investigator 1 United Therapeutics Corporation $3,822.00 06/11/2025 Non-covered Recipient Entity
The Ohio State University
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389373
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 06/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786463
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 06/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786465
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,438.40 05/09/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794273
Principal investigator 1 United Therapeutics Corporation $2,099.16 05/07/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389351
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14.00 05/02/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220818154
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 05/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786459
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 05/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786461
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 04/23/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786467
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 04/23/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786469
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 04/23/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786471
Principal investigator 1 Boehringer Ingelheim International GmbH $1.50 04/23/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786473
Principal investigator 1 United Therapeutics Corporation $2,165.80 04/23/2025 Non-covered Recipient Entity
The Ohio State University
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389367
Principal investigator 1 United Therapeutics Corporation $526.50 04/23/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242389383
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,465.90 04/09/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220794261
Principal investigator 1 United Therapeutics Corporation $1,234.80 04/09/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389349
Principal investigator 1 United Therapeutics Corporation $1,274.00 04/09/2025 Non-covered Recipient Entity
The Ohio State University
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389365
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20.53 04/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220818140
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,174.40 03/19/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794271
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,510.10 03/11/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220794259
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220786519
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220786547
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220786549
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 03/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220818138
Principal investigator 1 United Therapeutics Corporation $750.96 02/26/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389335
Principal investigator 1 United Therapeutics Corporation $2,469.60 02/26/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389337
Principal investigator 1 United Therapeutics Corporation $2,548.00 02/26/2025 Non-covered Recipient Entity
The Ohio State University
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389341
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 02/25/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786451
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 02/25/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786453
Principal investigator 1 Boehringer Ingelheim International GmbH $5.04 02/25/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786455
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/25/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786457
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 02/25/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220786521
Principal investigator 1 Boehringer Ingelheim International GmbH $28.04 02/25/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220786523
Principal investigator 1 Boehringer Ingelheim International GmbH $8.88 02/25/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220786525
Principal investigator 1 Boehringer Ingelheim International GmbH $8.88 02/25/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220786527
Principal investigator 1 Boehringer Ingelheim International GmbH $8.88 02/25/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220786529
Principal investigator 1 Boehringer Ingelheim International GmbH $8.88 02/25/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220786531
Principal investigator 1 Boehringer Ingelheim International GmbH $3.20 02/25/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220786533
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $683.80 02/17/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220794257
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,062.80 02/14/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794269
Principal investigator 1 United Therapeutics Corporation $4,074.84 02/12/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389339
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $715.00 02/10/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794267
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,367.60 02/06/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794237
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220786517
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220786539
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220786541
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 02/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220786543
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 02/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220786545
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,976.00 02/01/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220794235
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 02/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220818136
Principal investigator 1 United Therapeutics Corporation $4,204.20 01/29/2025 Non-covered Recipient Entity
The Ohio State University
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389343
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 01/27/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786445
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 01/27/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786447
Principal investigator 1 Boehringer Ingelheim International GmbH $1.50 01/27/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220786449
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,586.84 01/27/2025 Non-covered Recipient Entity
Ohio State University
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis No dispute reported 06/30/2026 1235995008
Principal investigator 1 United Therapeutics Corporation $526.50 01/22/2025 Non-covered Recipient Entity
The Ohio State University
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242389381
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,510.10 01/21/2025 Non-covered Recipient Entity
Ohio State University-Wexner Medical Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220794255
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220786515
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220786535
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220786537
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 01/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220786551
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 01/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220786553
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 01/01/2025 Covered Recipient Teaching Hospital
The Ohio State University Hospital
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220818134